Catalyst event

RELX PLC (RELX)

From KEDI Global Longevity Bio Index (KGLB)

RELX reported H1 2026 underlying revenue growth of 7%, adjusted operating-profit growth of 9%, and reaffirmed its full-year outlook for strong underlying growth.

Korean translation

RELX가 2026년 상반기 기초 매출 7% 성장과 조정 영업이익 9% 성장을 보고하고 연간 강한 기초 성장 전망을 재확인함.